vs
Civeo Corp（CVEO）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Civeo Corp的1.3倍（$207.3M vs $161.6M），Civeo Corp净利率更高（-4.0% vs -62.0%，领先58.0%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 7.1%），Civeo Corp自由现金流更多（$14.5M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -1.4%）
希维欧公司（Civeo Corporation）是一家美国住宿服务跨国企业，从石油国家国际公司（Oil States International）拆分而来，目前是在纽约证券交易所挂牌上市的公众公司，主要为能源等行业项目提供人员住宿配套服务解决方案。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CVEO vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $161.6M | $207.3M |
| 净利润 | $-6.5M | $-128.6M |
| 毛利率 | 22.7% | — |
| 营业利润率 | -0.1% | -54.7% |
| 净利率 | -4.0% | -62.0% |
| 营收同比 | 7.1% | 25.9% |
| 净利润同比 | 58.1% | 3.5% |
| 每股收益（稀释后） | $-0.58 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $161.6M | $207.3M | ||
| Q3 25 | $170.5M | $159.9M | ||
| Q2 25 | $162.7M | $166.5M | ||
| Q1 25 | $144.0M | $139.3M | ||
| Q4 24 | $151.0M | $164.6M | ||
| Q3 24 | $176.3M | $139.5M | ||
| Q2 24 | $188.7M | $147.0M | ||
| Q1 24 | $166.1M | $108.8M |
| Q4 25 | $-6.5M | $-128.6M | ||
| Q3 25 | $-455.0K | $-180.4M | ||
| Q2 25 | $-3.3M | $-115.0M | ||
| Q1 25 | $-9.8M | $-151.1M | ||
| Q4 24 | $-15.4M | $-133.2M | ||
| Q3 24 | $-5.1M | $-133.5M | ||
| Q2 24 | $8.2M | $-131.6M | ||
| Q1 24 | $-5.1M | $-170.7M |
| Q4 25 | 22.7% | — | ||
| Q3 25 | 25.7% | — | ||
| Q2 25 | 25.3% | — | ||
| Q1 25 | 20.4% | — | ||
| Q4 24 | 18.6% | — | ||
| Q3 24 | 21.4% | — | ||
| Q2 24 | 25.4% | — | ||
| Q1 24 | 21.5% | — |
| Q4 25 | -0.1% | -54.7% | ||
| Q3 25 | 4.1% | -106.9% | ||
| Q2 25 | 1.7% | -64.8% | ||
| Q1 25 | -3.8% | -102.6% | ||
| Q4 24 | -6.7% | -74.3% | ||
| Q3 24 | 0.0% | -94.6% | ||
| Q2 24 | 6.9% | -79.1% | ||
| Q1 24 | -1.1% | -151.9% |
| Q4 25 | -4.0% | -62.0% | ||
| Q3 25 | -0.3% | -112.8% | ||
| Q2 25 | -2.0% | -69.0% | ||
| Q1 25 | -6.8% | -108.5% | ||
| Q4 24 | -10.2% | -80.9% | ||
| Q3 24 | -2.9% | -95.7% | ||
| Q2 24 | 4.4% | -89.5% | ||
| Q1 24 | -3.1% | -156.8% |
| Q4 25 | $-0.58 | $-1.28 | ||
| Q3 25 | $-0.04 | $-1.81 | ||
| Q2 25 | $-0.25 | $-1.17 | ||
| Q1 25 | $-0.72 | $-1.57 | ||
| Q4 24 | $-1.04 | $-1.34 | ||
| Q3 24 | $-0.36 | $-1.40 | ||
| Q2 24 | $0.56 | $-1.52 | ||
| Q1 24 | $-0.35 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.4M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $174.4M | $-80.0M |
| 总资产 | $477.4M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $14.4M | $421.0M | ||
| Q3 25 | $12.0M | $202.5M | ||
| Q2 25 | $14.6M | $176.3M | ||
| Q1 25 | $28.4M | $127.1M | ||
| Q4 24 | $5.2M | $174.0M | ||
| Q3 24 | $17.9M | $150.6M | ||
| Q2 24 | $7.4M | $480.7M | ||
| Q1 24 | $16.8M | $112.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $43.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $174.4M | $-80.0M | ||
| Q3 25 | $182.5M | $9.2M | ||
| Q2 25 | $209.4M | $151.3M | ||
| Q1 25 | $220.7M | $144.2M | ||
| Q4 24 | $236.4M | $255.0M | ||
| Q3 24 | $282.2M | $346.8M | ||
| Q2 24 | $297.4M | $432.4M | ||
| Q1 24 | $297.4M | $140.3M |
| Q4 25 | $477.4M | $1.5B | ||
| Q3 25 | $491.1M | $1.2B | ||
| Q2 25 | $508.8M | $1.3B | ||
| Q1 25 | $423.8M | $1.3B | ||
| Q4 24 | $405.1M | $1.5B | ||
| Q3 24 | $477.6M | $1.5B | ||
| Q2 24 | $483.2M | $1.6B | ||
| Q1 24 | $513.1M | $1.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.3M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $14.5M | $-100.8M |
| 自由现金流率自由现金流/营收 | 8.9% | -48.6% |
| 资本支出强度资本支出/营收 | 3.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $2.1M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $19.3M | $-99.8M | ||
| Q3 25 | $13.8M | $-91.4M | ||
| Q2 25 | $-2.3M | $-108.3M | ||
| Q1 25 | $-8.4M | $-166.5M | ||
| Q4 24 | $9.5M | $-79.3M | ||
| Q3 24 | $35.7M | $-67.0M | ||
| Q2 24 | $32.4M | $-77.0M | ||
| Q1 24 | $6.0M | $-190.7M |
| Q4 25 | $14.5M | $-100.8M | ||
| Q3 25 | $8.2M | $-92.7M | ||
| Q2 25 | $-6.8M | $-110.7M | ||
| Q1 25 | $-13.7M | $-167.8M | ||
| Q4 24 | $1.8M | $-79.5M | ||
| Q3 24 | $28.2M | $-68.6M | ||
| Q2 24 | $27.0M | $-79.0M | ||
| Q1 24 | $372.0K | $-193.9M |
| Q4 25 | 8.9% | -48.6% | ||
| Q3 25 | 4.8% | -58.0% | ||
| Q2 25 | -4.2% | -66.5% | ||
| Q1 25 | -9.5% | -120.5% | ||
| Q4 24 | 1.2% | -48.3% | ||
| Q3 24 | 16.0% | -49.2% | ||
| Q2 24 | 14.3% | -53.7% | ||
| Q1 24 | 0.2% | -178.2% |
| Q4 25 | 3.0% | 0.5% | ||
| Q3 25 | 3.3% | 0.8% | ||
| Q2 25 | 2.8% | 1.5% | ||
| Q1 25 | 3.7% | 1.0% | ||
| Q4 24 | 5.1% | 0.1% | ||
| Q3 24 | 4.2% | 1.2% | ||
| Q2 24 | 2.8% | 1.4% | ||
| Q1 24 | 3.4% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.93× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CVEO
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
